Kurt Adzema
Analyst · Ruplu Bhattacharya from Bank of America. Your line is open
Thanks Hartmut. We started off the quarter strong and on track to meet our original outlook. However, as the quarter progressed, we started to be impacted by COVID-19. We first saw this as our employees in China were delayed in returning from Chinese New Year. Secondly, there were delays in our Chinese supply chain, which have been shutdown as well and we supply to our operations worldwide as well as the operations of our customers. Thirdly, we saw the impact to the timing and cost associated with the logistics of the supply chain, especially freight. Finally, in March, we saw the impact of the shelter-in-place and similar restrictions, on both our operations as well as the operations of our customers. The fact that many of Sanmina's products are considered essential and as such are subject to certain exemptions from shelter-in-place or similar restrictions helped mitigate the impact, but we were still impacted. As a management team, we focused on what we could control, namely optimization of our cost structure, limitation in new capital expenditures to only the most essential items, and cash generation. With that, I'd like to walk you through the details of the quarter. If you could please turn to Slide 3. Second quarter revenue of $1.6 billion, was down 13.6% sequentially and 9.1% lower than the midpoint of our original outlook provided in January. Again this was primarily due to the impact of COVID-19 as we previously discussed. As you know we withdrew our original outlook back in March. Q2 non-GAAP gross margin was 6.9%, down relative to the prior quarter. This was primarily the result of under absorption due to lower revenue levels, manufacturing inefficiencies, and additional costs caused by COVID-19. There were certain limitations based on government mandates in certain geographies, which prevented Sanmina from optimizing our cost base for the lower revenue levels, which we would do in the normal course. Q2 operating expenses declined relative to the prior quarter to $62.8 million as we focused on reducing spending as the uncertainty around COVID-19 started to become apparent. Q2 non-GAAP other expenses were approximately $13.5 million. This was up approximately $9.3 million relative to the prior quarter. This was primarily due to a loss of approximately $5.1 million related to deferred compensation assets, primarily as the result of the decline in the stock market and other financial assets in the second quarter. This compares to a gain of $2.0 million in the first quarter. As a reminder gains or losses related to deferred compensation assets have no net impact on non-GAAP earnings per share. Deferred compensation gains or losses are equally offset with corresponding increases or decreases in manufacturing and operating expenses. Finally Q2 non-GAAP fully diluted earnings per share declined to $0.32 due to the impact of COVID-19 on revenue and gross margins. As the uncertainty related to COVID became evident we limited new capital expenditures to only the most decentralized items. Net capital expenditures were approximately $16.4 million in the quarter. Depreciation, amortization was approximately $28 million. If you now please turn to slide 4, here you can see additional income statement details related to the quarter and the associated comparisons. If you now please turn to slide 5 and I will discuss our two segments both of our segments revenues and gross margins were impacted by COVID-19 relative to our original outlook for the quarter. As you can see on the left IMS segment revenue declined to approximately $1.3 billion, non-GAAP gross margins down to 5.8%. On the right hand side you'll see components, products and services revenues declined to $327 million. Non-GAAP gross margins were down to 10.6%. Now please turn to slide 6, on this page you can see our revenues by end market. While many of Sanmina’s products are considered essential and such are subject to certain exemptions to shelter in and place and other restrictions. Many of these markets were still impacted by the supply chain disruptions caused by COVID-19. If you would now please turn to slide 7, our balance sheet remains very strong despite the challenging quarter related to COVID-19 we generated approximately $136 million of cash from operations, and approximately $119 million of free cash flow. Cash and cash equivalents were approximately $1.1 billion at the end of the quarter. Towards the end of the quarter given the uncertainty related to COVID-19 we decided to draw down $650 million of our $700 million revolver. We did not use any of the cash last quarter, and we do not expect to use any of this cash in the third quarter. As I mentioned before, we generated free cash flow in the second quarter and expect to generate free cash flow in the third quarter. We continue to maintain a low debt to cash ratio 0.9. Our term loan has a balance of $366 million and matures in November 2023. During the quarter we repurchased approximately 2.4 million shares for approximately $61 million. For the year-to-date we've repurchased 2.7 million shares and a total of $70 million. We will continue to be opportunistic and repurchasing shares. Inventory was up approximately $40 million and inventory terms declined to 6.9. This was due to the manufacturing inefficiencies and disruptions in supply chain caused by COVID-19. Cash cycle days were 61.7. Non-GAAP pre-tax return on invested capital was 14.6. I would now ask you to turn to slide 8. Here you can see additional balance sheet details related to the quarter and the associated comparisons. Now if you please turn to Slide 9, we’ll discuss the third quarter outlook while our Chinese operations are up and running and the Chinese supply chain is improving daily we still foresee continued impact to our operations in the third quarter and the rest of the world. Although again mitigated to some extent by the fact that many of the products we manufacture are considered essential. In addition there remains uncertainty as it relates to the impact of shelter and place and other similar restrictions on our supply chain outside of China as well as on our customers. The impact of COVID-19 and the macroeconomic environment will continue to evolve as the quarter progresses. Again as a management team we will remain focused on what we can control namely optimization of our cost structure, limitation on new capital expenditures only to the most essential items and cash generation. Our outlook for the third quarter is that revenue will be relatively flat in the range of $1.5 billion to $1.6 billion reflective of the continued impact of COVID-19. Customer demand for the quarter is expected to be relatively stable with the exception of weakness in Automotive. We expect non-GAAP gross margins will be in the range of 6.4% to 6.9% as we continue to be impacted by COVID-19. This relates to under absorption continued manufacturing, inefficiencies and additional costs. Non-GAAP operating expenses should be approximately $61 million to $63 million. We continue to be focused on reducing operating expenses given macroeconomic uncertainty. We expect non-GAAP operating margin to be in the range of 2.5% to 3%. We expect non-GAAP other expenses to be approximately $10 million. Our non-GAAP tax rate should be of around 22%. We expect non-GAAP fully-diluted share count to be around 70 million shares. When you consider all this guidance or outlook for non-GAAP earnings per share for the quarter is in the range of $0.30 to $0.40. Adjusting for an estimated stock-based compensation of $0.12 cents per share, GAAP diluted earnings per share is expected to be between $0.18 and $0.28 cents. Again we planned to limit new capital expenditures to only the most essential items. We expect capital expenditures to be around $17 million, while we expect depreciation and amortization to be around $28 million Finally despite the continued impact of COVID-19, we expect to continue to generate free cash flow in the quarter. As I sit here today, there are a lot of variables which are changing every day, as we manage through the COVID-19 crisis. Not only do I believe Sanmina has navigated through these well to-date, I believe we are positioning ourselves well with our customers and our key markets to benefit during the ultimate recovery. And with that, I'll turn it back to Hartmut for additional comments.